CA Patent

CA2800509A1 — Inhibitors of hcv ns5a

Assigned to Presidio Pharmaceuticals Inc · Expires 2011-12-01 · 14y expired

What this patent protects

Provided herein are compounds, pharmaceutical compositions and combination therapies for inhibition of hepatitis C.

USPTO Abstract

Provided herein are compounds, pharmaceutical compositions and combination therapies for inhibition of hepatitis C.

Drugs covered by this patent

daclatasvir-dihydrochloride (DACLATASVIR DIHYDROCHLORIDE)

Patent Metadata

Patent number: CA2800509A1
Jurisdiction: CA
Classification: —
Expires: 2011-12-01
Drug substance claim: No
Drug product claim: No
Assignee: Presidio Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.